AUROPHARMA

Aurobindo Pharma Share Price

₹1,400.7
+ 4.2 (0.3%)
  • Advice
  • Hold
03 November, 2024 18:33 BSE: 524804 NSE: AUROPHARMA ISIN: INE406A01037

Start SIP in Aurobindo Pharma

Start SIP

Aurobindo Pharma Performance

Day Range

  • Low 1,394
  • High 1,410
₹ 1,400

52 Week Range

  • Low 835
  • High 1,592
₹ 1,400
  • Open Price1,407
  • Previous Close1,397
  • Volume39844

Aurobindo Pharma Chart

  • Over 1 Month -2.61%
  • Over 3 Month -2.95%
  • Over 6 Month + 21.13%
  • Over 1 Year + 63.64%

Aurobindo Pharma Key Statistics

P/E Ratio 23.1
PEG Ratio 0.3
Market Cap Cr 81,353
Price to Book Ratio 2.7
EPS 33.3
Dividend 0.3
Relative Strength Index 34.02
Money Flow Index 10.79
MACD Signal -18.39
Average True Range 36.25

Aurobindo Pharma Investment Rating

  • Master Rating:
  • Aurobindo Pharma has an operating revenue of Rs. 29,718.37 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 15% is great, ROE of 10% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Aurobindo Pharma Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 2,4602,8942,6642,6482,3643,484
Operating Expenses Qtr Cr 1,9612,1192,2102,1241,9682,856
Operating Profit Qtr Cr 499775482545422692
Depreciation Qtr Cr 6765646660115
Interest Qtr Cr 515361373249
Tax Qtr Cr 1172016313090171
Net Profit Qtr Cr 329579624416336645
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 11,26213,226
Operating Expenses Annual Cr 8,42211,061
Operating Profit Annual in Cr 2,2241,731
Depreciation Cr 255435
Interest Annual Cr 183115
Tax Annual Cr 503384
Net Profit Annual Cr 1,9541,230
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 1,7151,821
Cash from Investing Activity Annual Cr -160-3,460
Cash from Financing Annual Activity Cr -1,8371,719
Net Cash Flow Annual Cr -28281
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 19,72317,914
Fixed Assets Annual Cr 2,5523,927
Total Non Current Assets Annual Cr 17,91515,210
Total Current Assets Annual Cr 7,2399,724
Total Assets Annual Cr 25,15424,934
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 337306
ROE Annual % 107
ROCE Annual % 139
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2717
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 7,5677,5807,2717,1516,7916,379
Operating Expenses Qtr Cr 5,9475,9075,7505,8465,6995,471
Operating Profit Qtr Cr 1,6201,6731,6011,3731,1511,002
Depreciation Qtr Cr 404354423418327346
Interest Qtr Cr 1118976685756
Tax Qtr Cr 406323322324242224
Net Profit Qtr Cr 919909936757571506
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 29,55925,146
Operating Expenses Annual Cr 23,15921,137
Operating Profit Annual in Cr 5,8433,719
Depreciation Cr 1,5221,245
Interest Annual Cr 290140
Tax Annual Cr 1,211685
Net Profit Annual Cr 3,1731,928
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 2,4352,387
Cash from Investing Activity Annual Cr -4,256-3,978
Cash from Financing Annual Activity Cr 8001,814
Net Cash Flow Annual Cr -1,021223
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 29,84326,840
Fixed Assets Annual Cr 17,76615,818
Total Non Current Assets Annual Cr 20,86618,344
Total Current Assets Annual Cr 24,20621,546
Total Assets Annual Cr 45,07239,890
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 509458
ROE Annual % 117
ROCE Annual % 1510
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2216

Aurobindo Pharma Technicals

EMA & SMA

Current Price
₹1,400.7
+ 4.2 (0.3%)
pointer
  • Bullish Moving Average
  • ___
  • 3
  • Bearish Moving Average
  • ___
  • 13
  • 20 Day
  • ₹1,445.35
  • 50 Day
  • ₹1,458.71
  • 100 Day
  • ₹1,409.50
  • 200 Day
  • ₹1,287.91
  • 20 Day
  • ₹1,454.16
  • 50 Day
  • ₹1,497.09
  • 100 Day
  • ₹1,423.36
  • 200 Day
  • ₹1,265.49

Aurobindo Pharma Resistance and Support

PIVOT
₹1,401.57
Resistance
First Resistance 1,409.13
Second Resistance 1,417.57
Third Resistance 1,425.13
RSI 34.02
MFI 10.79
MACD Single Line -18.39
MACD -24.13
Support
First Support 1,393.13
Second Support 1,385.57
Third Supoort 1,377.13

Aurobindo Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 41,408 1,393,379 33.65
Week 643,573 33,118,287 51.46
1 Month 751,566 35,849,698 47.7
6 Month 1,419,012 68,864,638 48.53

Aurobindo Pharma Result Highlights

Aurobindo Pharma Synopsis

NSE-Medical-Generic Drugs

Aurobindo Pharma Ltd. is a leading integrated global pharmaceutical company . Initially specializing in Semi-Synthetic Penicillins, the company has expanded its product portfolio to include a wide range of therapeutic areas such as neurosciences, cardiovascular, anti-retrovirals, gastroenterology, and antibiotics. Aurobindo Pharma operates 25 manufacturing and packaging facilities approved by major regulatory bodies like the USFDA and UK MHRA, and it distributes its products in over 150 countries. The company's growth is supported by robust R&D capabilities and a strong commitment to operational excellence.
Market Cap 81,109
Sales 10,715
Shares in Float 27.88
No of funds 745
Yield 0.32
Book Value 4.15
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.14
Beta 0.63

Aurobindo Pharma Shareholding Pattern

Owner NameSep-24Jun-24Mar-24Dec-23
Promoters 51.82%51.8%51.83%51.83%
Mutual Funds 18.53%19.17%17.83%14.7%
Insurance Companies 4.66%5.19%5.03%5.53%
Foreign Portfolio Investors 16.59%16.73%18.01%20.72%
Financial Institutions/ Banks 0.07%
Individual Investors 5.33%5.47%5.51%5.65%
Others 3%1.64%1.79%1.57%

Aurobindo Pharma Management

Name Designation
Mr. M Ramasubramanian Kumar Chairman & Ind.Dire (Non-Exe)
Mr. K Nithyananda Reddy Vice Chairman & Mng.Director
Mr. M Madan Mohan Reddy Whole Time Director
Mr. P V Ramprasad Reddy Non Executive Director
Dr. Satakarni Makkapati Non Executive Director
Mr. P Sarath Chandra Reddy Non Executive Director
Mr. Girish P Vanvari Independent Director
Mrs. Savita Mahajan Independent Director
Mr. Santanu Mukherjee Independent Director
Dr. Deepali Pant Joshi Independent Director

Aurobindo Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Aurobindo Pharma Corporate Action

Date Purpose Remarks
2024-08-10 Quarterly Results
2024-07-18 Buy Back of Shares To consider buyback for equity shares per share(125%)Interim Dividend
2024-05-25 Audited Results
2024-02-10 Quarterly Results & Interim Dividend
2023-11-09 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-02-20 INTERIM Rs.1.50 per share(150%)Second Interim Dividend
2023-11-20 INTERIM Rs.3.00 per share(300%)First Interim Dividend
2023-02-17 INTERIM Rs.3.00 per share(300%)Interim Dividend
2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend

Aurobindo Pharma FAQs

What is Share Price of Aurobindo Pharma ?

Aurobindo Pharma share price is ₹1,400 As on 03 November, 2024 | 18:19

What is the Market Cap of Aurobindo Pharma ?

The Market Cap of Aurobindo Pharma is ₹81352.9 Cr As on 03 November, 2024 | 18:19

What is the P/E ratio of Aurobindo Pharma ?

The P/E ratio of Aurobindo Pharma is 23.1 As on 03 November, 2024 | 18:19

What is the PB ratio of Aurobindo Pharma ?

The PB ratio of Aurobindo Pharma is 2.7 As on 03 November, 2024 | 18:19

Is it a good time to invest in Aurobindo Pharma?

Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

How many times have Aurobindo Pharma given dividends since 2000?

Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

What is the stock price CAGR of Aurobindo Pharma?

The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

What is the ROE of Aurobindo Pharma?

Aurobindo Pharma has an ROE of 24% which is exceptional.

What is Aurobindo Pharma’s debt to equity?

Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23